Evidence map›Paper›PMID 32706905›Full record

ArticleClinical and experimental immunology2020

Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.

A Uzawa, Y Kojima, Y Ozawa, M Yasuda, Y Onishi, H Akamine, N Kawaguchi, K Himuro, S Kuwabara

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

A UzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID 0000-0001-9252-1863
Y KojimaDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Y OzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
M YasudaDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Y OnishiDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
H AkamineDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
N KawaguchiDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
K HimuroDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
S KuwabaraDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenia gravis (MG) is an autoantibody-mediated inflammatory disease of the neuromuscular junction. Biomarkers indicating disease activity in MG are warranted. Recently, the soluble urokinase plasminogen activator receptor (suPAR) has been reported to be associated with inflammation, tissue damage, disease activity and prognosis in various diseases, including autoimmune diseases. In this study, serum suPAR levels were measured in 40 patients with anti-acetylcholine receptor antibody-positive MG and 30 controls, and their correlations with clinical variables and severity scale scores were investigated. We identified that serum suPAR levels significantly correlated with MG activities of daily living scale (Spearman's ρ = 0·45; P = 0·004) and MG Foundation of America classification (Spearman's ρ = 0·37; P = 0·02) at serum sampling, but not with anti-acetylcholine receptor antibody titers. In conclusion, serum suPAR levels can be a candidate for a novel biomarker of disease activity in anti-acetylcholine receptor antibody-positive MG.

Indexed as

Myasthenia GravisReceptors, Urokinase Plasminogen ActivatorSeverity of Illness IndexAgedBiomarkersFemaleHumansMaleMiddle AgedPilot ProjectsBiomarkersPLAUR protein, humanReceptors, Urokinase Plasminogen Activatoranti-acetylcholine receptor antibodybiomarkerdisease activitymyasthenia gravisneuromuscular junctionurokinase plasminogen activator receptor

Identifiers

PMID32706905
PMCPMC7670129
OpenAlexW3044235115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.